2023 - Research.com Medicine in Denmark Leader Award
His scientific interests lie mostly in Internal medicine, Cardiology, Myocardial infarction, Heart failure and Surgery. Hazard ratio, Ejection fraction, Heart disease, Atrial fibrillation and Confidence interval are the primary areas of interest in his Internal medicine study. His Cardiology research incorporates elements of Clinical endpoint and Randomized controlled trial.
His Myocardial infarction research is multidisciplinary, incorporating perspectives in Stroke, ACE inhibitor and Risk factor. In his work, Captopril is strongly intertwined with Valsartan, which is a subfield of Heart failure. His Surgery study incorporates themes from Clinical trial, Risk of mortality, Epidemiology, Cohort study and Comorbidity.
The scientist’s investigation covers issues in Internal medicine, Cardiology, Heart failure, Myocardial infarction and Hazard ratio. He merges Internal medicine with In patient in his research. Lars Køber studied Cardiology and Surgery that intersect with Epidemiology.
The Heart failure study combines topics in areas such as Incidence, Clinical endpoint, Randomized controlled trial, Dapagliflozin and Valsartan. His work carried out in the field of Myocardial infarction brings together such families of science as Heart disease and Risk factor. His study in Hazard ratio is interdisciplinary in nature, drawing from both Interquartile range, Cohort study, Cohort and Comorbidity.
Lars Køber mainly investigates Internal medicine, Cardiology, Heart failure, Hazard ratio and Ejection fraction. As part of his studies on Internal medicine, he often connects relevant areas like Dapagliflozin. His Cardiology study integrates concerns from other disciplines, such as Clinical endpoint and Interquartile range.
His work in Heart failure tackles topics such as Diabetes mellitus which are related to areas like Mace and Kidney disease. His research in Hazard ratio intersects with topics in Blood pressure and Cohort study. Lars Køber works mostly in the field of Ejection fraction, limiting it down to topics relating to Placebo and, in certain cases, Empagliflozin.
His primary areas of investigation include Internal medicine, Heart failure, Cardiology, Ejection fraction and Hazard ratio. His Atrial fibrillation, Confidence interval and Myocardial infarction study in the realm of Internal medicine interacts with subjects such as In patient. His Heart failure research is multidisciplinary, relying on both Genome-wide association study, Cohort study, Diabetes mellitus, Electrocardiography and Mendelian inheritance.
His research integrates issues of Magnetic resonance imaging, Cardiac magnetic resonance imaging, Clinical endpoint, Fibrosis and Hyperkalemia in his study of Cardiology. His Ejection fraction study combines topics from a wide range of disciplines, such as Valsartan, Placebo, Randomized controlled trial and MEDLINE. His Hazard ratio research includes themes of Absolute risk reduction, Interquartile range, Proportional hazards model and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
Stamatis Adamopoulos;Stefan D. Anker;Volkmar Falk;Lars Køber.
European Heart Journal (2012)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
John J.V. McMurray;Stamatis Adamopoulos;Stefan D. Anker;Angelo Auricchio.
European Journal of Heart Failure (2012)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray;Scott D. Solomon;Silvio E. Inzucchi;Lars Køber.
The New England Journal of Medicine (2019)
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Marc A. Pfeffer;John J.V. McMurray;Eric J. Velazquez;Jean-Lucien Rouleau.
The New England Journal of Medicine (2003)
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
Niklas Nielsen;Jørn Wetterslev;Tobias Cronberg;David Erlinge.
The New England Journal of Medicine (2013)
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Køber L;Torp-Pedersen C;Carlsen Je;Bagger H.
The New England Journal of Medicine (1995)
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Nagesh S Anavekar;John J V McMurray;Eric J Velazquez;Scott D Solomon.
The New England Journal of Medicine (2004)
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
Marcus D. Flather;Salim Yusuf;Lars Køber;Marc Pfeffer.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer;Brian L. Claggett;Rafael Diaz;Kenneth Dickstein.
The New England Journal of Medicine (2015)
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
C Torp-Pedersen;M Møller;P E Bloch-Thomsen;L Køber.
The New England Journal of Medicine (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: